Genmab A/S (OCSE:GMAB)
kr 2041 15 (0.74%) Market Cap: 131.83 Bil Enterprise Value: 103.26 Bil PE Ratio: 24.66 PB Ratio: 4.09 GF Score: 92/100

Genmab A/S at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2022 / 12:00PM GMT
Release Date Price: kr2719 (-0.73%)
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

All right. Perfect. I think we are ready to go. Good morning, everybody. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Very pleased to have Genmab with us this morning.

Briefly before we get started, I need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures.

So with that, I'm pleased to have Jan van de Winkel, the CEO of Genmab; and Anthony Pagano, who is the CFO. Jan, I thought maybe a good place to start would be to talk about epco and maybe just update people on where we are in terms of filing and path to market there.

Questions & Answers

Jan G.J. van de Winkel;S;Co;Founder
Genmab A;President & CEO

/-- -

Thanks for having us here today. We

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot